|
2023
|
Invention
|
Methods of treating cancer with long-acting topoisomerase i inhibitor. The disclosure provides me... |
|
|
Invention
|
Treating cancer with long-acting topoisomerase i inhibitor. The disclosure provides method of tre... |
|
|
Invention
|
Synergistic cancer treatment.
Conjugates of topoisomerase I inhibitors linked to a macromolecule... |
|
|
Invention
|
Protocol for minimizing toxicity of combination dosages and imaging agent for verification.
Adva... |
|
2022
|
Invention
|
Hydrogels with biodegradable crosslinking.
Hydrogels that degrade under appropriate conditions o... |
|
|
Invention
|
High-throughput microemulsification membrane.
The present disclosure is related to high-throughp... |
|
|
Invention
|
High-throughput microemulsification membrane. The present disclosure is related to high-throughpu... |
|
2021
|
Invention
|
Extended release hydrogel conjugates of c-natriuretic peptides.
Provided herein are extended rel... |
|
|
Invention
|
Extended release hydrogel conjugates of c-natriuretic peptides. Provided herein are extended rele... |
|
2020
|
Invention
|
Conjugated inhibitors of dna damage response.
Provided herein are releasable conjugates of inhib... |
|
|
Invention
|
Conjugated inhibitors of dna damage response. Provided herein are releasable conjugates of inhibi... |
|
|
Invention
|
Steam sterilization of hydrogels crosslinked by beta-eliminative linkers.
Methods for the steam ... |
|
|
Invention
|
Steam sterilization of hydrogels crosslinked by beta-eliminative linkers. Methods for the steam s... |
|
|
Invention
|
Slow-release cytokine conjugates.
This disclosure generally relates to releasable cytokine conju... |
|
|
Invention
|
Slow-release cytokine conjugates. This disclosure generally relates to releasable cytokine conjug... |
|
|
Invention
|
Improved conjugation linkers.
Provided are β-eliminative linkers suitable for the conjugation of... |
|
|
Invention
|
Improved conjugation linkers. Provided are β-eliminative linkers suitable for the conjugation of ... |
|
|
Invention
|
Improved conjugation linkers. Provided are ß-eliminative linkers suitable for the conjugation of ... |
|
2019
|
Invention
|
Hydrogels with biodegradable crosslinking. Hydrogels that degrade under appropriate conditions of... |
|
|
Invention
|
Aseptic method and apparatus to prepare sterile formulations of drug-linked hydrogel microspheres... |
|
|
Invention
|
Synergistic cancer treatment. Conjugates of topoisomerase I inhibitors linked to a macromolecule ... |
|
|
Invention
|
Protocol for minimizing toxicity of combination dosages and imaging agent for verification. Advan... |
|
|
Invention
|
Synergistic cancer treatment. in situin situ in combination with one or more of an assessed defec... |
|
2018
|
Invention
|
Conjugates of somatostatin analogues. Conjugates of carriers and hydrogels for controlling the bi... |
|
|
Invention
|
Slow-release conjugates of sn-38. Conjugates of SN-38 that provide optimal drug release rates and... |
|
2017
|
Invention
|
Extended release conjugates of exenatide analogs.
Extended-release conjugates of stabilized GLP-... |
|
|
Invention
|
Extended release conjugates of exenatide analogs. Extended-release conjugates of stabilized GLP-1... |
|
2015
|
Invention
|
Reagents for thiol conjugation and conjugates formed therefrom. Reagents for preparing stabilized... |
|
2014
|
Invention
|
Conjugates of somatostatin and its analogs. Conjugates of carriers and hydrogels for controlling ... |
|
|
Invention
|
Prodrugs and drug-macromolecule conjugates having controlled drug release rates. The present inve... |
|
|
Invention
|
Sealants having controlled degration.
The invention provides sealants wherein biodegradable hydr... |
|
|
Invention
|
Sealants having controlled degradation. The invention provides sealants wherein biodegradable hyd... |
|
2012
|
Invention
|
Peg conjugates of exenatide.
Slow release forms of exenatide wherein exenatide is releasably lin... |
|
2011
|
Invention
|
Controlled release from solid supports. The invention relates to solid supports useful in medical... |
